mark this post. too many bad side effects and 2 deaths in the clinical trial there is no way the FDA will approve this. there are other drugs on the market that are not as toxic.
Explain why EU approved it????? also granted reimbursement codes........why??? why???
Explain why US FDA approved its use at 6 US CancerCenters under Expanded Access Program even while its under review?
Dude, get your head off that bong.......Chemosat WILL be approved along with its 2nd generation filter which is now being used in EU and 6 USA centers Expanded indications will follow. Parternships will follow.
It's headed to $2.5 soon and after ODAC positive nod.........its headed to $3.5.
Next comes FDA approval and potential buy-out at $6-8/share.
Sentiment: Strong Buy
If you are going to fabricate lies, at least know what you are talking about.
You have no idea what Delcath does. GOOF!!!
But, hey thanks anyway. It's always a positive sign when goodball bashers start to post their #$%$.
Dcth presented data at asco that shows their system causes severe neutropenia and 2 people died in the clinical trial from neutropenic sepsis there is no way the fda will approve this due to safety issues
Patient population being studied were TERMINALLY ILL. Also, there is conclusive causality with the 2 deaths. Severe neutropenia an expected side effect of all CHEMO agents. Chemosat system offers STATISCALLY SIGNIFICANT efficacy with similar or lesser side effect profile compared to traditional options. Also, EU real world use data validates enhanced safety from GEN-2 filter due to improved filtration. US FDA will take all this in to consideration. This is the very reason they even allowed Expanded Use Access at US Canter centers prior to FDA approval decision. Wake up Johnny. Wake up.
Sentiment: Strong Buy
no I am not short I was thinking of buying but I did my DD and didnt like what I discovered anyway I no its not a drug but I was just saying that there are drugs that are safe and being used to treat liver cancer anyway its your money but we will see who is uninformed on May 2 when the advisory panel rejects it then in june the FDA will follow with an official rejection